CGT Live Article: Verdot's FlexiPro Chrom Platform Helps Address Bioprocessing Needs for Gene Therapy Manufacturing
09 Jun 24
Sébastien Lefebvre, VERDOT® Vice President of R&D, was interviewed by CGT Live®.
“Manufacturing of adeno-associated virus (AAV) vector-based gene therapy products is a complex and expensive process with many steps. As such, companies working on development and manufacturing of gene therapy products are often looking for new tools to streamline their workflows. ..”
Reach out to learn more about how we can help you with your downstream processing needs.